Management of Uterine Sarcomas


Uterine sarcomas are rare malignant tumors characterized by a great clinical and histopathological diversity. The aim of this work is to analyze the difficulties of diagnosis, therapeutic and prognosis posed by these tumors. Thirty-seven patients with uterine sarcoma, collected in the service Radiotherapy and Oncology, University Ibn Rochd of Casablanca between January 2000 and December 2007 were included in this study retrospective. The average patient age was 50 years (17-76). The bleeding was present in all patients, isolated in 54% of cases associated with pelvic pain in 24.6% and a mass abdomino-pelvic in seven patients. The average time of evolution was 10 months. The main histological type was found leiomyosarcoma. Twenty four patients in our series underwent total hysterectomy without annexial conservation. The surgery R0 was obtained in 43% of cases. The sarcomas were classified as stage IV in 51.4%. Adjuvant radiotherapy was indicated in 13 patients. After a mean of 20 months, half of patients evaluable presented a local relapse and/or metastatic, the third of cases were tumor progression while complete remission was maintained in 18.5% of cases. Uterine sarcomas are rare malignant mesenchymal tumor, which often occur in women after menopause. The main prognostic factors are hormonal status of the patient, stage clinical, histological type, histological grade and quality surgical excision. The management of uterine sarcomas is multidisciplinary, based mainly on surgery remains the only means of cure. Adjuvant radiotherapy allows decreased risk of local recurrence, with no impact on survival achieved at best 30% at 5 years. The role of chemotherapy remains confirm.

Share and Cite:

A. Naim, Z. Bouchbika, M. Aksim, N. Benchakroune, H. Jouhadi, N. Tawfiq, S. Sahraoui, S. Zamiati and A. Benider, "Management of Uterine Sarcomas," Journal of Cancer Therapy, Vol. 3 No. 5, 2012, pp. 621-626. doi: 10.4236/jct.2012.35079.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] S. E. Brooks, M. Zhan, T. Cote and C. R. Baquet, “Surveillance, Epidemiology, and End Results Analysis of 2677 Cases of Uterine Sarcoma 1989-1999,” Gynecologic Oncology, Vol. 93, No. 1, 2004, pp. 204-208. doi:10.1016/j.ygyno.2003.12.029
[2] A. Tinelli, “FIGO Staging for Uterine Sarcomas,” International Journal of Gynecology & Obstetrics, Vol. 104, No. 3, 2009, p. 179. doi:10.1016/j.ijgo.2008.12.009
[3] B. Harlow, N. Weiss and S. Lofton, “The Epidemiology of Sarcomas of the Uterus,” Journal of the National Cancer Institute, Vol. 76, No. 3, 1986, pp. 399-402.
[4] R. Nordal and S. Thoresen, “Uterine Sarcoma in Norway 1956-1992: Incidence, Survival and Mortality,” European Journal of Cancer, Vol. 33, No. 6, 1997, pp. 907-911.doi:10.1016/S0959-8049(97)00040-3
[5] N. S. Reed, “Uterine Sarcomas: The Biggest Challenge?’ Clinical Oncology, Vol. 14, No. 1, 2002, pp. 50-53. doi:10.1053/clon.2001.0043
[6] R. E. Curtis, D. M. Freedman, M. E. Sherman and J. F. Fraumeni Jr, “Risk of Malignant Mixed Mullerian Tumors after Tamoxifen Therapy for Breast Cancer,” Journal of the National Cancer Institute, Vol. 96, No. 1, 2004, pp. 70-74. doi:10.1093/jnci/djh007
[7] E. D’Angelo and J. Prat, “Uterine Sarcomas: A Review,” Gynecologic Oncology, Vol. 116, No. 1, 2009, pp. 3-6. doi:10.1016/j.ijgo.2008.12.008
[8] M. Abbes, B. Guillaume, J. Vershoore and M. Namer, “A Propos de 27cas de Forme Rare du Cancer du Corps de l’Utérus,” Revue Francaise de Gynécologie et d’Obstétri que, Vol. 79, No. 2, 1984, pp. 97-100.
[9] S. G. El Haloui, F. Bensaid, S. Nabil, R. Bezzad, S. El Fihri, M. T. Alaoui, “Les Sarcomes Utérins à Propos de 7cas Avec Revue de la Littérature,” Revue Francaise de Gynécologie et d’Obstétrique,Vol. 91, No. 3, 1996, pp. 94-100.
[10] E. Oliva, P. B. Clement and R. H. Young, “Mesenchymal Tumors of the Uterus: Selected Topics Emphasizing Diagnostic Pitfalls,” Current Diagnostic Pathology, Vol. 8, No. 4, 2002, pp. 282-286doi:10.1054/cdip.2002.0126
[11] E. Gonzalez-Bosquet, J. M. Martinez-Palones, J. González-Bosquet, A. García Jiménez and Xercavins, “Uterine Sarcoma: A Clinicopathological Study of 93 Cases,” European Journal of Gynaecological Oncology, Vol. 18, No. 3, 1997, pp. 192-195.
[12] M. Nickie-Psikuta and K. Gawrychowski, “Different Types and Different Prognosis Study of 310 Uterine Sarcomas,” European Journal of Gynaecological Oncology, Vol. 14, 1993, pp. 105-113.
[13] S. Leibsohn, G. d’Albaing and S. Mishell, “Leiomyosarcoma in a Series of Hysterectomies Performed for Presumed Uterine Leiomyomas,” American Journal of Obstetrics and Gynecology, Vol. 162, No. 4, 1990, pp. 68-76.
[14] R. Aviram, Y. Ochshorn, O. Markovitch, A. Fishman, I. Cohen, M. M. Altaras, et al., “Uterine Sarcomas versus Leiomyomas: Gray-Scale and Doppler Sonographic Findings,” Journal of Clinical Ultrasound, Vol. 33, No. 1, 2005, pp.10-13. doi:10.1002/jcu.20075
[15] S. Taieb, F. Narducci, A. Chevalier, M. C. Baranzelli, L. Ceugnart and E. Leblanc, “Imagerie des Sarcomes Utérins,” Imagerie de la Femme, Vol. 18, No. 4, 2008, pp. 229-235. doi:10.1016/S1776-9817(08)74626-1
[16] A. M. Maffione, M. Piva, C. S. Tsamita, C. Nanni, P. Castellucci, V. Ambrosini, et al., “Positron-Emission Tomography in Gynaecologic Malignancies,” Archives of Gynecology and Obstetrics, Vol. 280, No. 4, 2009, pp. 521-528. doi:10.1007/s00404-009-0979-2
[17] K. Oda, S. Okada, T. Nei, T. Shirai, M. Takahashi, Y. Sano, et al., “Cytodiagnostic Problems in Uterine Sarcoma. Analysis According to a Novel Classification of Tumor Growth Types,” Acta Cytologica, Vol. 48, No. 2, 2004, pp. 181-186. doi:10.1159/000326313
[18] M. Nickie-Psikuta and K. Gawrychowski, “Different Types and Different Prognosis Study of 310 Uterine Sarcomas,” European Journal of Gynaecological Oncology, Vol. 14, 1993, pp. 105-113.
[19] E. Deniaud-Alexandre, L. Chauveinc, A. de la Rochefordière, X. Sastre and K. B. Clough, “Intérêt des Traitements Adjuvants Dans les Sarcomes Utérins: Expérience de l’Institut Curie,” Cancer/Radiothérapie, Vol. 5, No. 6, 2001, pp. 743-749. doi:10.1016/S1278-3218(01)00133-0
[20] F. Ferrer, S. Sabater, B. Farrus, F. Guedea, A. Rovirosa and L. Anglada, “Impact of Radiotherapy on Local Control and Survival in Uterine Sarcomas: A Retrospective Study from the Group Oncologic Catala-Occita,” International Journal of Radiation Oncology, Biology, Physics, Vol. 4, No. 1, 1999, pp. 47-52. doi:10.1016/S0360-3016(98)00515-X
[21] G. Echt, J. Jepson, J. Steel, B. Langholz, G. Luxton and W. Hernandez, “Treatment of Uterine Sarcomas,” Cancer, Vol. 66, No. 1, 1990, pp. 35-39. doi:10.1002/1097-0142(19900701)66:1<35::AID-CNCR2820660108>3.0.CO;2-V
[22] B. Larson, C. Silfversward, B. Nilsson and F. Patterson, “Mixed Mullerian Tumours of the Uterus-Prognotic Factors: A Clinical and Histopathologic Study of 147 Cases,” Radiotherapy and Oncology, Vol. 17, No. 2, 1990, pp. 123-132. doi:10.1016/0167-8140(90)90100-B
[23] S. Kanjeekal, A. Chambers, M. F. Fung and S. Verma, “Systemic Therapy for Advanced Uterine Sarcoma: A Systemic Review of the Literature,” Gynecologic Oncology, Vol. 97, No. 2, 2005, pp. 624-637. doi:10.1016/j.ygyno.2005.01.041
[24] P. Pautier, “Sarcomes Utérins,” Oncologie, Vol. 9, No. 2, 2007, pp. 137-143. doi:10.1007/s10269-006-0545-5
[25] Y. S. Kuo, P. Timmins and S. V.Blank, “Phase II Trial of Thalidomide for Advanced and Recurrent Gynecologic Sarcoma: A Brief Communication from the New York Phase II Consortium,” Gynecologic Oncology, Vol. 100, No. 1, 2006, pp. 160-165. doi:10.1016/j.ygyno.2005.08.033
[26] S. E. Brooks, M. Zhan, T. Cote and C. R. Baquet, “Surveillance, Epidemiology, and End Results Analysis of 2677 Cases of Uterine Sarcoma 1989-1999,” Gynecologic Oncology, Vol. 93, No. 1, 2004, pp. 204-208. doi:10.1016/j.ygyno.2003.12.029
[27] L. Benoit, L. Arnould, N. Cheynel, S. Goui, F. Collin, J. Fraisse, et al., “The Role of Surgery and Treatment Trends in Uterine Sarcoma,” European Journal of Surgical Oncology, Vol. 31, No. 4, 2005, pp. 434-442. doi:10.1016/j.ejso.2005.01.010
[28] B. A. Goff, L. W. Rice, D. Fleischacker, H. G. Muntz, S. S. Falkenberry, N. Nikrui, et al., “Uterine Sarcoma and Endometrial Stromal Sarcoma: Lymph Node Metastases and Sites of Recurrence,” Gynecologic Oncology, Vol. 50, No. 1, 1993, pp. 105-109. doi:10.1006/gyno.1993.1172

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.